Brief: Quantum Genomics FY Net Loss Widens To 12 Million Euros

Quantum Genomics SA

28/03/2019 17:51

March 28 (Reuters) - QUANTUM GENOMICS SA  ALQGC.PA :
    * QUANTUM GENOMICS REPORTS FULL-YEAR 2018 FINANCIAL RESULTS
    * FY CASH POSITION ROSE TO EUR 14.8 MILLION, COVERING
STUDIES
SCHEDULED FOR 2019
    * FY FREE CASH FLOW (NET CASH FLOW RELATING TO BUSINESS
OPERATIONS) WAS -EUR 11.1 MILLION FOR PERIOD.
    * CURRENTLY CONDUCTING A PHARMACOKINETIC STUDY
    * ALL PATIENTS HAVE BEEN ENROLLED AND RESULTS OF THIS STUDY
WILL
BE AVAILABLE IN Q2 2019.
    * FY OPERATING LOSS EUR 13.6 MILLION VERSUS LOSS OF EUR 10.4
MILLION YEAR AGO
    * IN FIELD OF HEART FAILURE, QUANTUM GENOMICS IS PREPARING
FOR
ENROLMENT OF FIRST PATIENTS IN PHASE IIB QUORUM STUDY BEGINNING
IN Q2 2019.
    * IN FIELD OF HEART FAILURE RESULTS EXPECTED IN H2 2020.
    * FY NET LOSS EUR 12 MILLION VERSUS LOSS OF EUR 9.4 MILLION
YEAR
AGO
    * IN FIELD OF HYPERTENSION, QUANTUM GENOMICS IS PREPARING TO
ENTER
PHASE III DEVELOPMENT,
    * IN FIELD OF HYPERTENSION THIS STUDY INITIATION IS PLANNED
FOR H2
2019.
    * SIGNING A PARTNERSHIP REMAINS A MAIN OBJECTIVE FOR QUANTUM
GENOMICS

Source text for Eikon:  ID:nGNXVxnJk 
Further company coverage:  ALQGC.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))